Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
SUSPENDED
NCT07464028
PHASE2
Terazosin And Metabolic Energetics in Parkinson's Disease
Sponsor: Ergun Y. Uc
View on ClinicalTrials.gov
Summary
This study investigates if Terazosin can improve metabolism in PD.
Official title: Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)
Key Details
Gender
All
Age Range
50 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2028-07-01
Completion Date
2031-07-01
Last Updated
2026-10-09
Healthy Volunteers
No
Conditions
Interventions
DRUG
Terazosin 5 MG
This drug increases glycolysis in Parkinson's disease.
DRUG
Placebo
Placebo control for Terazosin
Locations (1)
University of Iowa
Iowa City, Iowa, United States